These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

203 related items for PubMed ID: 7577460

  • 1. Importance of P450 reductase activity in determining sensitivity of breast tumour cells to the bioreductive drug, tirapazamine (SR 4233).
    Patterson AV, Barham HM, Chinje EC, Adams GE, Harris AL, Stratford IJ.
    Br J Cancer; 1995 Nov; 72(5):1144-50. PubMed ID: 7577460
    [Abstract] [Full Text] [Related]

  • 2. Overexpression of human NADPH:cytochrome c (P450) reductase confers enhanced sensitivity to both tirapazamine (SR 4233) and RSU 1069.
    Patterson AV, Saunders MP, Chinje EC, Talbot DC, Harris AL, Strafford IJ.
    Br J Cancer; 1997 Nov; 76(10):1338-47. PubMed ID: 9374381
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Adaptation of human tumor cells to tirapazamine under aerobic conditions: implications of increased antioxidant enzyme activity to mechanism of aerobic cytotoxicity.
    Elwell JH, Siim BG, Evans JW, Brown JM.
    Biochem Pharmacol; 1997 Jul 15; 54(2):249-57. PubMed ID: 9271329
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. The 2-nitroimidazole EF5 is a biomarker for oxidoreductases that activate the bioreductive prodrug CEN-209 under hypoxia.
    Wang J, Foehrenbacher A, Su J, Patel R, Hay MP, Hicks KO, Wilson WR.
    Clin Cancer Res; 2012 Mar 15; 18(6):1684-95. PubMed ID: 22167409
    [Abstract] [Full Text] [Related]

  • 11. Nitric oxide synthases catalyze the activation of redox cycling and bioreductive anticancer agents.
    Garner AP, Paine MJ, Rodriguez-Crespo I, Chinje EC, Ortiz De Montellano P, Stratford IJ, Tew DG, Wolf CR.
    Cancer Res; 1999 Apr 15; 59(8):1929-34. PubMed ID: 10213502
    [Abstract] [Full Text] [Related]

  • 12. Enzymology of the reductive bioactivation of SR 4233. A novel benzotriazine di-N-oxide hypoxic cell cytotoxin.
    Walton MI, Workman P.
    Biochem Pharmacol; 1990 Jun 01; 39(11):1735-42. PubMed ID: 2344370
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Metabolism of the bioreductive cytotoxin SR 4233 by tumour cells: enzymatic studies.
    Wang J, Biedermann KA, Wolf CR, Brown JM.
    Br J Cancer; 1993 Feb 01; 67(2):321-5. PubMed ID: 8431360
    [Abstract] [Full Text] [Related]

  • 19. The effect of functional groups on reduction and activation of quinone bioreductive agents by DT-diaphorase.
    Fourie J, Oleschuk CJ, Guziec F, Guziec L, Fiterman DJ, Monterrosa C, Begleiter A.
    Cancer Chemother Pharmacol; 2002 Feb 01; 49(2):101-10. PubMed ID: 11862423
    [Abstract] [Full Text] [Related]

  • 20. Tirapazamine-induced DNA damage measured using the comet assay correlates with cytotoxicity towards hypoxic tumour cells in vitro.
    Siim BG, van Zijl PL, Brown JM.
    Br J Cancer; 1996 Apr 01; 73(8):952-60. PubMed ID: 8611431
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.